Literature DB >> 33188905

Transition to HBeAg-negative chronic hepatitis B virus infection is associated with reduced cccDNA transcriptional activity.

Aleksei Suslov1, Marie-Anne Meier2, Sylvia Ketterer1, Xueya Wang1, Stefan Wieland3, Markus Hermann Heim4.   

Abstract

BACKGROUND & AIMS: HBeAg seroconversion during the natural history of chronic hepatitis B (CHB) is associated with a strong drop in serum HBV DNA levels and a reduction of intrahepatic covalently closed circular DNA (cccDNA) content. Of particular interest is the transition to HBeAg-negative chronic infection (ENCI). ENCI, previously known as inactive carrier state, is characterized by very low or negative viremia and the absence of liver disease. The molecular mechanisms responsible for the transition to ENCI and for the control of viral replication in ENCI are still poorly understood.
METHODS: To identify which step(s) in the viral life cycle are controlled during the transition to ENCI, we quantified cccDNA, pre-genomic RNA (pgRNA), total HBV RNA and DNA replicative intermediates in 68 biopsies from patients in different phases of CHB.
RESULTS: HBeAg seroconversion is associated with a reduction of cccDNA amounts as well as transcriptional activity. Silencing of cccDNA is particularly pronounced in ENCI, where there was ~46 times less pgRNA per cccDNA compared to HBeAg-negative CHB. Furthermore, a subgroup of patients with HBeAg-negative CHB can be characterized by reduced replication efficiency downstream of pgRNA.
CONCLUSIONS: The reduction in serum viral load during the transition to ENCI seems to primarily result from strong inhibition of the transcriptional activity of cccDNA which can be maintained in the absence of liver disease. LAY
SUMMARY: During the natural course of chronic hepatitis B virus infections, the immune response can gain control of viral replication. Quantification of viral DNA and RNA in liver biopsies of patients in different stages of chronic hepatitis B allowed us to identify the steps in the viral life cycle that are affected during the transition from active to inactive disease. Therapeutic targeting of these steps might induce sustained inhibition of viral transcription.
Copyright © 2020 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Biopsy; Liver; Replication; Viral control

Mesh:

Substances:

Year:  2020        PMID: 33188905     DOI: 10.1016/j.jhep.2020.11.003

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  13 in total

1.  Inflammatory Gene Expression Associates with Hepatitis B Virus cccDNA- but Not Integrant-Derived Transcripts in HBeAg Negative Disease.

Authors:  Andrea Magri; James M Harris; Valentina D'Arienzo; Rosalba Minisini; Frank Jühling; Peter A C Wing; Rachele Rapetti; Monica Leutner; Barbara Testoni; Thomas F Baumert; Fabien Zoulim; Peter Balfe; Mario Pirisi; Jane A McKeating
Journal:  Viruses       Date:  2022-05-17       Impact factor: 5.818

2.  A Prospective Cohort Study of Novel Markers of Hepatitis B Virus Replication in Human Immunodeficiency Virus Coinfection.

Authors:  Raymond T Chung; Wendy C King; Marc G Ghany; Mauricio Lisker-Melman; Amanda S Hinerman; Mandana Khalili; Mark Sulkowski; Mamta K Jain; Eun-Young K Choi; Michael A Nalesnik; Atul K Bhan; Gavin Cloherty; David K Wong; Richard K Sterling
Journal:  Clin Gastroenterol Hepatol       Date:  2021-12-29       Impact factor: 13.576

Review 3.  Assessing immunological and virological responses in the liver: Implications for the cure of chronic hepatitis B virus infection.

Authors:  Tobias Boettler; Upkar S Gill; Lena Allweiss; Teresa Pollicino; John E Tavis; Fabien Zoulim
Journal:  JHEP Rep       Date:  2022-04-02

Review 4.  Transaminase Elevations during Treatment of Chronic Hepatitis B Infection: Safety Considerations and Role in Achieving Functional Cure.

Authors:  Andrew Vaillant
Journal:  Viruses       Date:  2021-04-23       Impact factor: 5.048

5.  Methylation profile of hepatitis B virus is not influenced by interferon α in human liver cancer cells.

Authors:  In Young Moon; Jin-Wook Kim
Journal:  Mol Med Rep       Date:  2021-08-13       Impact factor: 2.952

6.  Ongoing viral replication and production of infectious virus in patients with chronic hepatitis B virus suppressed below the limit of quantitation on long-term nucleos(t)ide therapy.

Authors:  Dara L Burdette; Scott Lazerwith; Jenny Yang; Henry L Y Chan; William E Delaney Iv; Simon P Fletcher; Tomas Cihlar; Becket Feierbach
Journal:  PLoS One       Date:  2022-04-01       Impact factor: 3.240

7.  PRKDC promotes hepatitis B virus transcription through enhancing the binding of RNA Pol II to cccDNA.

Authors:  Yao Fan; Yi Liang; Yu Liu; Hui Fan
Journal:  Cell Death Dis       Date:  2022-04-25       Impact factor: 9.685

8.  Dynamics of Hepatitis B Virus Pregenomic RNA in Chronic Hepatitis B Patients With Antiviral Therapy Over 9 Years.

Authors:  Jiali Pan; Yu Tian; Jinghang Xu; Hao Luo; Ning Tan; Yifan Han; Qian Kang; Hongyu Chen; Yuqing Yang; Xiaoyuan Xu
Journal:  Front Med (Lausanne)       Date:  2022-04-29

Review 9.  Humoral immunity in hepatitis B virus infection: Rehabilitating the B in HBV.

Authors:  Thomas Vanwolleghem; Tom Adomati; Stijn Van Hees; Harry L A Janssen
Journal:  JHEP Rep       Date:  2021-11-19

10.  Comparison of HBV RNA and Hepatitis B Core Related Antigen With Conventional HBV Markers Among Untreated Adults With Chronic Hepatitis B in North America.

Authors:  Marc G Ghany; Wendy C King; Mauricio Lisker-Melman; Anna S F Lok; Norah Terrault; Harry L A Janssen; Mandana Khalili; Raymond T Chung; William M Lee; Daryl T Y Lau; Gavin A Cloherty; Richard K Sterling
Journal:  Hepatology       Date:  2021-09-09       Impact factor: 17.298

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.